ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.95885
-0.08%
Brent Oil
83.635
0.01%
Bitcoin
59,348.66
0.38%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Tarsus Pharmaceuticals Inc (TARS)

  7. Tarsus Pharmaceuticals Inc (TARS) Noticias

TARS

Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:TARS
FechaHoraFuenteTítuloSímboloCompañía
01/05/202416:00GlobeNewswire Inc.Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
23/04/202407:30GlobeNewswire Inc.Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202416:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202415:30GlobeNewswire Inc.Tarsus to Participate at Upcoming Investor ConferencesNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202415:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202407:30GlobeNewswire Inc.Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202416:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202423:07GlobeNewswire Inc.Tarsus Announces Pricing of $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202415:37GlobeNewswire Inc.Tarsus Announces Proposed $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202415:32Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202415:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202415:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202405:00GlobeNewswire Inc.Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
22/02/202407:00GlobeNewswire Inc.Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme DiseaseNASDAQ:TARSTarsus Pharmaceuticals Inc
20/02/202416:00GlobeNewswire Inc.Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
31/01/202416:00GlobeNewswire Inc.Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks ConferenceNASDAQ:TARSTarsus Pharmaceuticals Inc
22/01/202416:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TARSTarsus Pharmaceuticals Inc
27/12/202315:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
11/12/202307:00GlobeNewswire Inc.Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex MitesNASDAQ:TARSTarsus Pharmaceuticals Inc
21/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TARSTarsus Pharmaceuticals Inc
09/11/202315:18Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:TARSTarsus Pharmaceuticals Inc
09/11/202315:05GlobeNewswire Inc.Tarsus Reports Third Quarter 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
09/11/202315:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARSTarsus Pharmaceuticals Inc
01/11/202317:35GlobeNewswire Inc.Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023NASDAQ:TARSTarsus Pharmaceuticals Inc
06/09/202307:00GlobeNewswire Inc.Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
30/08/202315:30GlobeNewswire Inc.Tarsus to Present at Upcoming Investor ConferencesNASDAQ:TARSTarsus Pharmaceuticals Inc
24/08/202308:00GlobeNewswire Inc.Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
10/08/202315:05GlobeNewswire Inc.Tarsus Reports Second Quarter 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
01/08/202321:30GlobeNewswire Inc.Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common StockNASDAQ:TARSTarsus Pharmaceuticals Inc
31/07/202315:29GlobeNewswire Inc.Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common StockNASDAQ:TARSTarsus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:TARS

Su Consulta Reciente

NASDAQ
TSLA
Tesla
SPI
SP500
S&P 500
AMEX
XLF
Financial Select Sector
NYSE
DIS
Walt Disney
NASDAQ
GOOGL
Alphabet
AMEX
XLV
Health Care Select Sector
COIN
SOLUSD
Solana
FX
EURUSD
Euro vs US Dollar
FX
EURMXN
Euro vs MXN
PM
XAUUSD
Gold vs US Dollar
NASDAQ
AMZN
Amazon.com
NYSE
MCD
McDonalds
NYSE
NKE
Nike
NYSE
VZ
Verizon Communications
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados